Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
2.5
USD
|
+1.63%
|
|
-0.79%
|
-22.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,167
|
3,541
|
2,126
|
907.1
|
540.2
|
522
|
-
|
-
|
Enterprise Value (EV)
1 |
2,636
|
2,713
|
1,317
|
330.6
|
91.47
|
232.5
|
446.2
|
479.4
|
P/E ratio
|
-14.2
x
|
-12.1
x
|
-7.89
x
|
-2.71
x
|
-1.54
x
|
-1.59
x
|
-1.6
x
|
-1.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
55.2
x
|
3,733
x
|
5,686
x
|
392
x
|
111
x
|
15.5
x
|
EV / Revenue
|
-
|
-
|
34.2
x
|
1,361
x
|
963
x
|
175
x
|
95
x
|
14.2
x
|
EV / EBITDA
|
-13.3
x
|
-10.8
x
|
-5.37
x
|
-1.03
x
|
-0.29
x
|
-0.9
x
|
-1.56
x
|
-1.38
x
|
EV / FCF
|
-14
x
|
-15
x
|
-6.38
x
|
-1.46
x
|
-0.38
x
|
-1.05
x
|
-1.94
x
|
-2.24
x
|
FCF Yield
|
-7.14%
|
-6.67%
|
-15.7%
|
-68.3%
|
-262%
|
-95.1%
|
-51.7%
|
-44.6%
|
Price to Book
|
4.17
x
|
3.28
x
|
2.32
x
|
1.36
x
|
1.06
x
|
1.43
x
|
2.14
x
|
-
|
Nbr of stocks (in thousands)
|
121,902
|
140,280
|
142,516
|
144,210
|
168,277
|
208,784
|
-
|
-
|
Reference price
2 |
25.98
|
25.24
|
14.92
|
6.290
|
3.210
|
2.500
|
2.500
|
2.500
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
38.49
|
0.243
|
0.095
|
1.331
|
4.696
|
33.76
|
EBITDA
1 |
-197.6
|
-250.8
|
-245.3
|
-321.2
|
-313.5
|
-257.5
|
-285.5
|
-346.9
|
EBIT
1 |
-202
|
-258.2
|
-255.8
|
-335.4
|
-327.7
|
-287.9
|
-306.4
|
-329.9
|
Operating Margin
|
-
|
-
|
-664.58%
|
-138,044.86%
|
-344,986.32%
|
-21,639.25%
|
-6,524.41%
|
-977.26%
|
Earnings before Tax (EBT)
1 |
-184.9
|
-250.2
|
-257
|
-332.6
|
-327.3
|
-277
|
-298.2
|
-312.2
|
Net income
1 |
-184.6
|
-250.2
|
-257
|
-332.6
|
-327.3
|
-278.8
|
-300.3
|
-317.1
|
Net margin
|
-
|
-
|
-667.74%
|
-136,885.6%
|
-344,489.47%
|
-20,948.71%
|
-6,395.03%
|
-939.27%
|
EPS
2 |
-1.830
|
-2.080
|
-1.890
|
-2.320
|
-2.090
|
-1.575
|
-1.567
|
-1.591
|
Free Cash Flow
1 |
-188.1
|
-181.1
|
-206.3
|
-225.7
|
-239.2
|
-221
|
-230.5
|
-214
|
FCF margin
|
-
|
-
|
-535.89%
|
-92,884.77%
|
-251,841.05%
|
-16,608.42%
|
-4,908.15%
|
-633.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.051
|
0.061
|
0.086
|
0.049
|
0.047
|
0.052
|
0.044
|
0.043
|
0.021
|
0.022
|
0.9498
|
0.0123
|
0.00647
|
0.0162
|
0.0162
|
EBITDA
1 |
-69.65
|
-76.3
|
-72.92
|
-78.63
|
-93.31
|
-95.56
|
-76.88
|
-59.4
|
-81.63
|
-65.95
|
-64.88
|
-64.45
|
-64.05
|
-69.14
|
-69.06
|
EBIT
1 |
-73.89
|
-79.99
|
-76.59
|
-82.49
|
-96.37
|
-99.07
|
-80.52
|
-62.98
|
-85.11
|
-69.5
|
-67.85
|
-70.47
|
-74.11
|
-77.22
|
-78.92
|
Operating Margin
|
-144,888.24%
|
-131,134.43%
|
-89,062.79%
|
-168,344.9%
|
-205,051.06%
|
-190,519.23%
|
-182,995.45%
|
-146,453.49%
|
-405,280.95%
|
-315,927.27%
|
-7,143.92%
|
-572,446.3%
|
-1,145,403.09%
|
-477,553.06%
|
-488,058.13%
|
Earnings before Tax (EBT)
1 |
-74.87
|
-79.85
|
-74.79
|
-83.15
|
-94.85
|
-98.7
|
-77.99
|
-61.32
|
-85.78
|
-65
|
-64.99
|
-67.76
|
-71.72
|
-74.37
|
-76.09
|
Net income
1 |
-74.87
|
-79.85
|
-74.79
|
-83.15
|
-94.85
|
-98.7
|
-77.99
|
-61.32
|
-85.78
|
-65
|
-65.45
|
-68.21
|
-72.08
|
-74.37
|
-76.09
|
Net margin
|
-146,800%
|
-130,901.64%
|
-86,961.63%
|
-169,689.8%
|
-201,802.13%
|
-189,815.38%
|
-177,247.73%
|
-142,593.02%
|
-408,466.67%
|
-295,454.55%
|
-6,890.58%
|
-554,096.02%
|
-1,114,037.87%
|
-459,923.75%
|
-470,583.36%
|
EPS
2 |
-0.5400
|
-0.5600
|
-0.5200
|
-0.5800
|
-0.6600
|
-0.6800
|
-0.5300
|
-0.3700
|
-0.5100
|
-0.3800
|
-0.3537
|
-0.3574
|
-0.3749
|
-0.3857
|
-0.3800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/4/22
|
8/9/22
|
11/2/22
|
2/28/23
|
5/3/23
|
8/2/23
|
11/2/23
|
3/14/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
531
|
828
|
809
|
576
|
449
|
289
|
75.8
|
42.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-188
|
-181
|
-206
|
-226
|
-239
|
-221
|
-231
|
-214
|
ROE (net income / shareholders' equity)
|
-27.7%
|
-29.3%
|
-25.8%
|
-42%
|
-55.5%
|
-67.6%
|
-78.5%
|
-
|
ROA (Net income/ Total Assets)
|
-24.8%
|
-25.7%
|
-22.7%
|
-35.8%
|
-44.7%
|
-51.8%
|
-61.2%
|
-
|
Assets
1 |
745.8
|
972.8
|
1,133
|
927.9
|
732.2
|
538.4
|
490.4
|
-
|
Book Value Per Share
2 |
6.220
|
7.690
|
6.430
|
4.610
|
3.040
|
1.740
|
1.170
|
-
|
Cash Flow per Share
|
-
|
-0.9600
|
-1.360
|
-1.540
|
-
|
-
|
-
|
-
|
Capex
1 |
50.8
|
66
|
21.4
|
5.19
|
1.52
|
2.65
|
2.17
|
5.03
|
Capex / Sales
|
-
|
-
|
55.72%
|
2,136.21%
|
1,595.79%
|
199.15%
|
46.11%
|
14.9%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Average target price
11.32
USD Spread / Average Target +352.62% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.12% | 522M | | +11.60% | 106B | | -4.68% | 24.28B | | -0.03% | 21.96B | | -8.17% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|